Eupraxia Pharmaceuticals Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EPRX | EIKN | INVA | ENTA | LXRX | TRDA | |
|---|---|---|---|---|---|---|
| Market cap | 446.66M | 346.11M | 1.54B | 310.19M | 658.53M | 197.02M |
| P/E (TTM) | — | — | 5.0 | — | — | — |
| Forward P/E | -6.5 | -1.0 | 9.6 | -4.5 | -7.8 | -1.6 |
| Price/book | 4.4 | 0.7 | 1.4 | 3.1 | 3.8 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +21.34% | −63.00% | +14.81% | −5.04% | +5.80% | −31.99% |
| Today | −1.74% | +15.14% | +1.58% | +2.70% | +1.37% | +7.20% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All EPRX news ›Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen
Posted by Kim Johansen on Nov 3rd, 2026 Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) from a strong sell rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen…
Eupraxia Pharmaceuticals: Promising Science, But Competition And Valuation Limit Upside
Eupraxia Pharmaceuticals looks overvalued amid clinical, commercial, and financial risks. - Eupraxia Pharmaceuticals (EPRX) is rated Sell due to overvaluation and high clinical, commercial, and financial risks for EP-104GI in eosinophilic…
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
Craig Hallum Biotech Catalyst Virtual Conference (October 22nd, 2026) Fireside Chat Date & Time: October 22, 2026, at 10:30am ET BIO-Europe (November 9-11, 2026) Stifel 2026 Healthcare Conference (November 10-12, 2026) Format: Fireside…
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Falls 8.7% – Here’s Why
Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) was down 8.7% during mid-day trading on Wednesday. The stock traded as low as C$6.62 and last traded at C$6.68. 1,522,825 shares were traded during trading, an increase of…
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
Investing News Network Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophil
Eupraxia Pharmaceuticals Inc. Announces Executive Changes
Eupraxia Pharmaceuticals Inc. announced that Dr. Jeff Millard joined Eupraxia as Executive Vice President, Technical Operations, effective July 13, 2026. Dr. Millard brings nearly 25 years of... Biotechnology & Medical Research Eupraxia…
Eupraxia Pharmaceuticals Inc.: Relative Strength Chart - Stock Toronto S.E.
Compare Eupraxia Pharmaceuticals Inc. with the company of your choice via a Relative Strength chart. Real-time EPRX price, Toronto S.E. stock exchange Relative Strength Chart Eupraxia Pharmaceuticals Inc. Biotechnology & Medical Research…
Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price Target
Eupraxia Pharmaceuticals has an average rating of buy and mean price target of $15.78, according to analysts polled by FactSet. ... Biotechnology & Medical Research Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price…
Eupraxia Pharmaceuticals Showcases EP-104GI EoE Data at Major Gastroenterology Meetings
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has shared an announcement. The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see…
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
The randomized, placebo-controlled portion of RESOLVE is recruiting patients at both doses under study. Eupraxia Pharmaceuticals (EPRX) will present three abstracts on its ongoing RESOLVE trial of EP-104GI at upcoming gastroenterology…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com7
- themarketsdaily.com2
- investingnews.com1
- manilatimes.net1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.